OptimizeRx (OPRX) Liabilities and Shareholders Equity (2010 - 2026)

OptimizeRx has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $167.3 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed 0.3% year-over-year to $167.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $683.8 million (up 1.0% YoY) and the FY2025 annual result came in at $176.9 million, up 3.36% from the prior year.
• Liabilities and Shareholders Equity slipped to $167.3 million in Q1 2026 per OPRX's latest filing, from $176.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $183.4 million in Q4 2023 and troughed at $121.3 million in Q2 2023.
• A 5-year average of $156.1 million and a median of $167.3 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity dropped 17.72% in 2023, then soared 42.49% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $134.7 million in 2022, then soared by 36.18% to $183.4 million in 2023, then declined by 6.66% to $171.2 million in 2024, then grew by 3.36% to $176.9 million in 2025, then fell by 5.46% to $167.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $167.3 million, $176.9 million, and $170.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.